Feed

KPRX

Kiora Pharmaceuticals, Inc.

KPRX · NASDAQ

$2.60 -0.76% (-$0.02)

1M +0.39%

Market Cap $11.5M

P/E Ratio -

Div. Yield -

ROE 63.39%

Bulios Fair Price

$2.24

13.8% downside

Current Price

$2.6

Undervalued Fair Value Overvalued

According to Bulios Fair Price, KPRX is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak

2/9

Valuation

100 /100

Cheap

P/B 0.68x

PEG N/A

P/E N/A

Growth

91 /100

Growing

Book val. growth 12.23%

FCF growth N/A

EPS growth N/A

Profitability

N/A

Op. margin N/A

Gross margin N/A

FCF margin N/A

Quality

0 /100

Poor

ROA 46.21%

ROIC 53.16%

Asset turnover 0.00x

Debt

100 /100

Low

Current ratio 8.97x

Debt/Equity 0.02x

Debt/Assets N/A

Stability

19 /100

Unstable

Profitable years 0

Beta -0.39x

EPS volatility 262.69%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about KPRX

Online

About the company

Kiora Pharmaceuticals, Inc. (KPRX) is a biotechnology company specializing in the research and development of drugs in the field of oncology and immunotherapy.

Sector

Healthcare

Industry

Biotechnology

CEO

Brian Strem

Employees

Headquarters

Encinitas

Upcoming events

06 NOV

Earnings

Upcoming earnings report

50d

⌘ K

StockBot Live

Market situation Wall Street

Wall Street slides as the Fed hikes interest rates

The S&P 500 -0.45% and Nasdaq -0.78% erased early gains after the Fed raised interest rates to fight inflation.

Ask about this

StockBot knows 80,000+ stocks worldwide